The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Open accessAbstract
BACKGROUND: Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H-antihistamines, even at high doses. In phase 2 trials, omalizumab, an anti-IgE monoclonal antibody [corrected] that targets IgE and affects mast-cell and basophil function, has shown efficacy in such patients. METHODS: In this phase 3, multicenter, randomized, double-blind study, we evaluated the efficacy and safety of omalizumab in patients with moderate-to-severe chronic idiopathic urticaria who remained symptomatic despite H-antihistamine therapy (licensed doses). We randomly assigned 323 patients to receive three subcutaneous injections, spaced 4 weeks apart, of omalizumab at doses of 75 mg, 150 mg, or 300 mg or placebo, followed by a 16-week observation period. The primary efficacy outcome was the change from baseline in a weekly itch-severity score (ranging from 0 to 21, with higher scores indicating more severe itching). RESULTS: The baseline weekly itch-severity score was approximately 14 in all four study groups. At week 12, the mean (±SD) change from baseline in the weekly itch-severity score was -5.1±5.6 in the placebo group, -5.9±6.5 in the 75-mg group (P=0.46), -8.1±6.4 in the 150-mg group (P=0.001), and -9.8±6.0 in the 300-mg group (P<0.001). Most prespecified secondary outcomes at week 12 showed similar dose-dependent effects. The frequency of adverse events was similar across groups. The frequency of serious adverse events was low, although the rate was higher in the 300-mg group (6%) than in the placebo group (3%) or in either the 75-mg or 150-mg group (1% for each). CONCLUSIONS: Omalizumab diminished clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of approved doses of H-antihistamines. (Funded by Genentech and Novartis Pharma; ClinicalTrials.gov number, NCT01292473.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Maurer, M., Weller, K., Bindslev-Jensen, C., Giménez-Arnau, A., Bousquet, P. J., Bousquet, J., Canonica, G. W., Church, M. K., Godse, K. V., Grattan, C. E. H., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02496.x · Cited by 843
Self-citationMacGlashan, D. W., Bochner, B. S., Adelman, D. C., Jardieu, P. M., Togias, A., McKenzie-White, J., Sterbinsky, S. A., Hamilton, R. G., & Lichtenstein, L. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1438 · Cited by 823
EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria
Zuberbier, T., Asero, R., Bindslev‐Jensen, C., Walter Canonica, G., Church, M. K., Giménez‐Arnau, A., Grattan, C. E. H., Kapp, A., Merk, H. F., Rogala, B., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02179.x · Cited by 731
Self-citationEAACI/GA²LEN/EDF/WAO guideline: management of urticaria
Zuberbier, T., Asero, R., Bindslev‐Jensen, C., Walter Canonica, G., Church, M. K., Giménez‐Arnau, A. M., Grattan, C. E. H., Kapp, A., Maurer, M., Merk, H. F., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02178.x · Cited by 527
Self-citationThe impact of chronic urticaria on the quality of life
O'DONNELL, B. F., LAWLOR, F., SIMPSON, J., MORGAN, M., & GREAVES, M. W. (1997) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1997.tb14895.x · Cited by 465
Omalizumab-induced reductions in mast cell FcεRI expression and function
Beck, L. A., Marcotte, G. V., MacGlashan, D., Togias, A., & Saini, S. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.06.032 · Cited by 456
Self-citationSaini, S., Rosen, K. E., Hsieh, H.-J., Wong, D. A., Conner, E., Kaplan, A., Spector, S., & Maurer, M. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.06.010 · Cited by 398
Self-citationChronic Urticaria and Angioedema
Kaplan, A. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011186 · Cited by 375
Self-citationGreaves, M. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322608 · Cited by 370
Maurer, M., Altrichter, S., Bieber, T., Biedermann, T., Bräutigam, M., Seyfried, S., Brehler, R., Grabbe, J., Hunzelmann, N., Jakob, T., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.04.038 · Cited by 360
Self-citationStaevska, M., Popov, T. A., Kralimarkova, T., Lazarova, C., Kraeva, S., Popova, D., Church, D. S., Dimitrov, V., & Church, M. K. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.047 · Cited by 327
Toubi, E., Kessel, A., Avshovich, N., Bamberger, E., Sabo, E., Nusem, D., & Panasoff, J. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00473.x · Cited by 299
Epidemiology of urticaria in Spain.
Gaig, P., Olona, M., Lejarazu, D. M., Caballero, T., Domínguez, F. J., Echechipia, S., Abujeta, J. L. G., Gonzalo, M., Lleonart, R., Martinez-Cocera, C., et al. (2004) · PubMed · Cited by 298
Treatment of chronic autoimmune urticaria with omalizumab
Kaplan, A. P., Joseph, K., Maykut, R. J., Geba, G. P., & Zeldin, R. K. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.07.006 · Cited by 286
Self-citationSafety and tolerability of omalizumab
Corren, J., Casale, T. B., Lanier, B., Buhl, R., Holgate, S., & Jimenez, P. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03214.x · Cited by 252
Self-citationOmalizumab and the risk of malignancy: Results from a pooled analysis
Busse, W., Buhl, R., Fernandez Vidaurre, C., Blogg, M., Zhu, J., Eisner, M. D., & Canvin, J. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.01.033 · Cited by 171
Self-citationMathias, S. D., Crosby, R. D., Zazzali, J. L., Maurer, M., & Saini, S. S. (2011) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2011.09.008 · Cited by 125
Self-citationNew concepts in chronic urticaria
Vonakis, B. M., & Saini, S. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.09.005 · Cited by 117
Self-citationEffects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge
Eckman, J. A., Sterba, P. M., Kelly, D., Alexander, V., Liu, M. C., Bochner, B. S., MacGlashan, D. W., & Saini, S. S. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.012 · Cited by 117
Self-citationShikiar, R., Harding, G., Leahy, M., & Lennox, R. D. (2005) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-3-36 · Cited by 107
Ong, Y. E., Menzies-Gow, A. N., Barkans, J. R., Benyahia, F., Ou, T.-T., Sun, Y., & Kay, A. B. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.05.035 · Cited by 97
Development of a daily diary for patients with chronic idiopathic urticaria
Mathias, S. D., Dreskin, S. C., Kaplan, A. P., Saini, S. S., Spector, S. L., & Rosén, K. E. (2010) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2010.06.011 · Cited by 73
Self-citationThe Impact of Chronic Idiopathic Urticaria on Quality of Life in Korean Patients
Kang, M. J., Kim, H. S., Kim, H. O., & Park, Y. M. (2009) · Annals of Dermatology · doi:10.5021/ad.2009.21.3.226 · Cited by 57
How IgE upregulates the allergic response
Saini, S. S., & MacGlashan, D. W. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00404-1 · Cited by 54
Self-citation
Cited by
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A. H., Baker, D., Ballmer‐Weber, B., Bernstein, J. A., Bindslev‐Jensen, C., Brzoza, Z., Buense Bedrikow, R., et al. (2018) · Allergy · doi:10.1111/all.13397 · Cited by 1,445
Self-citationZuberbier, T., Abdul Latiff, A. H., Abuzakouk, M., Aquilina, S., Asero, R., Baker, D., Ballmer‐Weber, B., Bangert, C., Ben‐Shoshan, M., Bernstein, J. A., et al. (2022) · Allergy · doi:10.1111/all.15090 · Cited by 1,263
Self-citationTargeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
The diagnosis and management of acute and chronic urticaria: 2014 update
Bernstein, J. A., Lang, D. M., Khan, D. A., Craig, T., Dreyfus, D., Hsieh, F., Sheikh, J., Weldon, D., Zuraw, B., Bernstein, D. I., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.02.036 · Cited by 682
Kaplan, A., Ledford, D., Ashby, M., Canvin, J., Zazzali, J. L., Conner, E., Veith, J., Kamath, N., Staubach, P., Jakob, T., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.05.013 · Cited by 573
Self-citation
Metadata
- Authors
- Maurer, M., Rosén, K., Hsieh, H.-J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., & Casale, T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-03-07
- Volume
- 368
- Issue
- 10
- Pages
- 924-935
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2121663010
- Cited by
- 1,105
- References
- 25
- FWCI
- 72.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.